Point72 Hong Kong LTD Eli Lilly & CO Call Options Transaction History

Point72 Hong Kong LTD

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $1.39 Million - $1.59 Million	4,700 Added 188.0%	7,200 $2.33 Million
Q2 2022 Aug 15, 2022	SELL	$278.73 - $327.27 $139,365 - $163,635	-500 Reduced 16.67%	2,500 $811,000
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $1.29 Million - $1.6 Million	-5,500 Reduced 64.71%	3,000 $859,000
Q4 2021 Feb 14, 2022	SELL	$224.85 - $279.04 $2.11 Million - $2.62 Million	-9,400 Reduced 52.51%	8,500 $2.35 Million
Q3 2021 Nov 15, 2021	SELL	$221.6 - $272.71 $3.04 Million - $3.74 Million	-13,700 Reduced 43.35%	17,900 $4.14 Million
Q2 2021 Aug 16, 2021	BUY	$180.55 - $233.54 $1.79 Million - $2.31 Million	9,900 Added 45.62%	31,600 $7.25 Million
Q1 2021 May 17, 2021	SELL	$164.32 - $212.72 $1.68 Million - $2.17 Million	-10,200 Reduced 31.97%	21,700 $4.05 Million
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $4.16 Million - $5.51 Million	31,900 New	31,900 $5.39 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.